COVID‐19‐associated mucormycosis involving the maxilla

It is important to increase the awareness and knowledge of head and neck surgeons about the recent surge of craniofacial mucormycosis in COVID‐19 patients because early diagnosis and appropriate treatment are essential to improve the outcomes. Here, we describe clinical features, treatment protocols...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasheminasab, Mahboube, Karizmeh, Mojtaba Salehi, Sharifi, Reza, Beshkar, Majid, Matloubi, Narges, Asadi, Amir Ali, Nazar, Elham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347695/
https://www.ncbi.nlm.nih.gov/pubmed/35937017
http://dx.doi.org/10.1002/ccr3.6165
Descripción
Sumario:It is important to increase the awareness and knowledge of head and neck surgeons about the recent surge of craniofacial mucormycosis in COVID‐19 patients because early diagnosis and appropriate treatment are essential to improve the outcomes. Here, we describe clinical features, treatment protocols, and outcomes of treatment in eight patients with COVID‐19‐associated mucormycosis in the maxilla. Consistent with the findings of previous studies, our experience in the management of these eight patients shows that early administration of amphotericin B and prompt aggressive surgery are essential for optimal control of the disease.

Ejemplares similares